SMTL ID : 6zgc.1 (3 other biounits)

Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530)

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.67 Å

Oligo State

monomer

Ligands

1 x H8H: N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE(Non-covalent)

H8H.1: 18 residues within 4Å: Chain A: V.16, Y.21, V.24, A.35, V.36, K.37, L.65, L.83, T.85, H.86, Y.87, H.88, E.89, G.91, S.92, K.142, L.145, A.155 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:V.16, A:V.24, A:V.24, A:K.37, A:L.65, A:Y.87, A:L.145, A:A.155 Hydrogen bonds: A:H.88

1 x K: POTASSIUM ION(Non-functional Binders)

K.2: 2 residues within 4Å: Ligands: PO4.3, PO4.4 No protein-ligand interaction detected (PLIP)

4 x PO4: PHOSPHATE ION(Non-functional Binders)

PO4.3: 10 residues within 4Å: Chain A: H.61, E.62, I.64, L.65, G.66, H.86, H.88, K.147, C.153 Ligands: K.2 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:G.66 Salt bridges: A:H.86, A:H.88, A:K.147 PO4.4: 5 residues within 4Å: Chain A: Y.87, H.88, K.147, K.148 Ligands: K.2 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:K.148 Salt bridges: A:H.88 PO4.5: 6 residues within 4Å: Chain A: K.140, K.142, T.180, R.182, Y.183 Ligands: PO4.6 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:R.182 Salt bridges: A:K.140, A:K.142 PO4.6: 5 residues within 4Å: Chain A: R.182, N.239, D.240, P.241 Ligands: PO4.5 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:D.240 Salt bridges: A:R.182

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Williams, E. et al., Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight (2021)

Release Date

2020-07-29

Peptides

Activin receptor type I: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Activin receptor type I

Related Entries With Identical Sequence